Litman Gregory Wealth Management LLC Grows Stock Position in Edwards Lifesciences Corporation (NYSE:EW)

Litman Gregory Wealth Management LLC raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 161,636 shares of the medical research company's stock after purchasing an additional 3,690 shares during the quarter. Edwards Lifesciences makes up approximately 1.0% of Litman Gregory Wealth Management LLC's portfolio, making the stock its 27th largest holding. Litman Gregory Wealth Management LLC's holdings in Edwards Lifesciences were worth $11,715,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $610,895,000. Vanguard Group Inc. raised its position in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares during the last quarter. Marshall Wace LLP raised its position in shares of Edwards Lifesciences by 55.7% in the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock worth $430,367,000 after purchasing an additional 2,079,642 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Edwards Lifesciences in the 4th quarter worth about $92,631,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW traded up $0.10 during trading hours on Thursday, reaching $76.24. The company had a trading volume of 4,140,708 shares, compared to its average volume of 5,267,965. Edwards Lifesciences Corporation has a 1-year low of $58.93 and a 1-year high of $88.56. The firm has a market cap of $44.72 billion, a PE ratio of 10.89, a price-to-earnings-growth ratio of 3.82 and a beta of 1.11. The business's 50 day moving average price is $76.42 and its 200-day moving average price is $73.41. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The business's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.66 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the transaction, the vice president directly owned 33,496 shares in the company, valued at $2,514,879.68. This trade represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,848 shares of company stock worth $2,314,488. Insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EW. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Evercore ISI boosted their price objective on Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Truist Financial cut their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $81.00.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.